

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that the Company's actual future results or performance may be materially different from what the Company expects. In this announcement, statements of, or references to, the intentions of the Company and/or any of its directors are made as of the date of this announcement. Any of these intentions may alter in light of future development.*



**AIM Vaccine Co., Ltd.**

**艾美疫苗股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 06660)**

## **VOLUNTARY ANNOUNCEMENT**

# **TETRAVALENT MENINGOCOCCAL CONJUGATE VACCINE CANDIDATE OFFICIALLY COMMENCED CLINICAL TRIAL**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that on March 15, 2023, the groups A, C, Y and W135 meningococcal polysaccharide conjugate vaccine (also known as tetraivalent meningococcal conjugate vaccine) candidate (“**MCV4 candidate**”) of the Group officially commenced Phase I single-center and open clinical trial at the Disease Control and Prevention Centre of Yanshan County, Yunnan. Subjects have commenced enrollment and 120 subjects are expected to be enrolled.

The MCV4 candidate may prevent epidemic cerebrospinal meningitis caused by groups A, C, Y and W135 neisseria meningitidis, and other invasive diseases.

**Meanwhile, investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**AIM Vaccine Co., Ltd.**

**Mr. Yan ZHOU**

*Chairman of the Board, Executive Director  
and Chief Executive Officer*

Hong Kong, March 17, 2023

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.*